Hong Kong Pharmaceuticals and Healthcare Report Q4 2012

Date: September 12, 2012
Pages: 90
Price:
US$ 1,295.00
Publisher: Business Monitor International
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: H1C2EC1410FEN
Leaflet:

Download PDF Leaflet

Includes 3 FREE quarterly updates

BMI View: Hong Kong will continue to be a market of moderate attractiveness to investors given its small pharmaceutical market size. However, its proximity to China, an increasingly ageing population and the dominance of patented medicines will continue to lure investors to the country.

Headline Expenditure Projections
  • Pharmaceuticals: HKD9.58bn (US$1.23bn) in 2011 to HKD10.37bn (US$1.33bn) in 2012; +8.3% in local currency terms and +8.5% in US dollar terms. Forecast upgraded due to reassessment of historic data.
  • Healthcare: HKD100.80bn (US$12.95bn) in 2011 to HKD106.62bn (US$13.72bn) in 2012; +5.8% in local currency terms and +6.0% in US dollar terms. Forecast upgraded due to reassessment of historic data.
  • Medical devices: HKD4.34bn (US$558mn) in 2011 to HKD4.65bn (US$598mn) in 2012; +7.1% in local currency terms and +7.2% in US dollar terms. Forecast slightly upgraded due to reassessment of historic data.
Risk/Reward Ratings: Hong Kong’s composite score in Q412 remains 60.2 out of 100, maintains its rank at seven, out of the 18 key regional markets in BMI’s Asia Pacific Risk/Reward Ratings. It has a high country rewards and industry/country risks scores that highlights the political and economic stability of the country; however its overall score is dragged down by a relatively small pharmaceutical market, in part due to its small population.

Key Trends And Developments
  • In July 2012, Ko Wing-man, the Secretary for Food and Health announced the expansion of a medical voucher scheme for senior citizens as part of Chief Executive Leung Chun-ying HKD7bn boost for elderly.
  • In June 2012, the Hong Kong Biotechnology Organisation and Australia-based AusBiotech signed a memorandum of understanding (MoU) to strengthen cooperation between Hong Kong and Australia. The MoU aims to encourage cooperation in biotechnology, particularly in fields of a mutual interest in economic and social development
BMI Economic View: Hong Kong’s economy continues to exhibit increasing signs of weakness as trade activity maintains its downward trajectory. Also, we are seeing strong signs of a marked slowdown in the retail sector, which, coupled with corrective pressure in the property market, means that consumption momentum should slow further going forward. We consequently see fit to maintain our bearish take on the economy and see real GDP growth coming in at 2.2% through 2012, versus consensus expectations for 3.0% expansion. We expect this economic weakness to extend into 2013 with economic growth seeing a marginal acceleration to 3.5%.

BMI Political View: Leung Chun-ying is likely to face a number of challenges at the start of his term as Hong Kong’s next Chief Executive. Boosting his popularity with the public and consolidating support within the civil administration are likely to be his first and most important tasks. Despite his alleged close ties with the central government in Beijing, we do not envisage any adverse changes to Hong Kong’s proinvestment business climate and expect the territory’s free-market philosophy to remain a mainstay of the economy.
Executive Summary
SWOT Analysis
Hong Kong Pharmaceuticals And Healthcare Industry SWOT
Hong Kong Political SWOT
Hong Kong Economic SWOT
Hong Kong Business Environment SWOT
Pharmaceutical Risk/Reward Ratings
  Table: Asia Pacific Pharmaceutical And Healthcare Risk/Reward Ratings, Q412
Rewards
Risks
Hong Kong – Market Summary
Regulatory Regime
  Table: Processed Applications
Regulatory Developments
Pharmaceutical Trade Regulations
Intellectual Property Issues
Counterfeit Drugs
Pricing And Reimbursement Regime
Public Procurement Of Medicines
Industry Trends And Developments
Epidemiology
Non-Communicable Diseases
Communicable Diseases
Healthcare Sector
Healthcare Sector Reform
Healthcare Financing
Healthcare Financing Developments
Healthcare Insurance
Biotechnology
Clinical Trials
Medical Devices
Industry Forecast Scenario
Overall Market Forecast
  Table: Pharmaceutical Sales Indicators 2008-2016
Key Growth Factors – Industry
  Table: Healthcare Expenditure Indicators 2008-2016
  Table: Healthcare Governmental Indicators 2008-2016
  Table: Healthcare Private Indicators 2008-2016
Key Growth Factors – Macroeconomic
Prescription Drug Market Forecast
  Table: Prescription Drug Sales Indicators 2008-2016
Patented Drug Market Forecast
  Table: Patented Drug Market Indicators 2008-2016
Generic Drug Market Forecast
  Table: Generic Drug Sales Indicators 2008-2016
Hong Kong Pharmaceuticals & Healthcare Report Q4 2012
© Business Monitor International Ltd Page
OTC Medicine Market Forecast
  Table: OTC Medicine Sales Indicators 2008-2016
Medical Device Market Forecast
  Table: Medical Devices Sales Indicators 2008-2016
Pharmaceutical Trade Forecast
  Table: Exports and Imports Indicators 2008-2016
Other Healthcare Indicators
Key Risks To BMI’s Forecast Scenario
Competitive Landscape
Pharmaceutical Industry
Traditional Chinese Medicine
Industry Developments
Pharmaceutical Supply Chain
Retail Pharmacy Sector
Company Profiles
Local Companies
Wuyi International Pharmaceutical
CK Life Sciences
South Asia Pharmamedic
C&Y Pharmaceutical Investment
Vida Laboratories
Multinational Companies
GlaxoSmithKline
Pfizer
Sanofi
Merck & Co
Novartis
Demographic Outlook
Hong Kong’s Population By Age Group, 1990-2020 (‘000)
Hong Kong’s Population By Age Group, 1990-2020 (% of total)
Hong Kong’s Key Population Ratios, 1990-2020
Hong Kong’s Rural And Urban Population, 1990-2020
Glossary
BMI Methodology
How We Generate Our Pharmaceutical Industry Forecasts
Pharmaceutical Risk/Reward Ratings Methodology
Ratings Overview
  Table: Pharmaceutical Risk/Reward Indicators
Weighting
  Table: Weighting Of Components
Sources
Hong Kong Pharmaceuticals and Healthcare Report Q1 2014 US$ 1,295.00 Nov, 2013 · 116 pages
Hong Kong Pharmaceuticals and Healthcare Report Q2 2014 US$ 1,295.00 Feb, 2014 · 113 pages
Hong Kong Pharmaceuticals and Healthcare Report Q3 2014 US$ 1,295.00 May, 2014 · 114 pages
OTC Healthcare in Hong Kong to 2014 US$ 495.00 Jul, 2010 · 189 pages
Pet Healthcare Market in Hong Kong to 2014 US$ 495.00 Mar, 2011 · 153 pages

Ask Your Question

Hong Kong Pharmaceuticals and Healthcare Report Q4 2012
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: